Contribute Try STAT+ Today

WASHINGTON — The Alzheimer’s Association stunned Washington last month when it urged Biogen to lower the price of its new Alzheimer’s drug — an extremely rare rebuke on drug pricing from a patient advocacy group, most of which normally sidestep the topic.

Pharma’s fiercest critics here — many of whom have blasted patient advocacy groups for not being more involved in the drug pricing debate — celebrated the Alzheimer’s Association’s audacity, especially as it risked being blackballed by its pharma funders. The statement made it clear that Biogen, as one crisis communications expert put it, “can’t afford to alienate its biggest cheerleader.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment